Fresh analysis indicates that people who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Published data in a leading medical journal points out that while overweight people can lose about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Users using such medications should be aware of the risk of quick weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery means a reversion to original weight within about a year and a half.
Comparing Therapies
The analysis, which reviewed 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
The team emphasize that individuals who shed pounds through lifestyle changes alone generally have a slower weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Experts suggest the way of the injections accounts for the accelerated regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in appetite is no longer kept in check, making binge eating a significant risk."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the significant potential of weight regain, the therapy should be considered long-term.
This perspective is echoed by drug manufacturers, who note that the findings "highlight the persistent character of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
People who have discontinued the medication report a intense return of cravings.
"It felt as if something flipping and I was suddenly extremely hungry," recalled an individual.
This difficulty is worsened if users have not adopted permanent lifestyle or habit modifications during treatment.
Significant Interest
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a magic fix and maintained weight loss likely depends on combined behavioural changes.
